Amgen to sell cholesterol drug at 60% discount direct to US consumers

Core Insights - Amgen has initiated direct-to-consumer sales of its cholesterol medication Repatha in the U.S. at a discounted cash price, responding to political pressure regarding drug pricing [1] Group 1: Company Actions - The launch of Repatha for direct consumer sales marks a strategic move by Amgen to enhance accessibility and affordability of its medication [1] - The discounted cash price indicates Amgen's effort to align with ongoing discussions about drug pricing reform in the U.S. [1] Group 2: Industry Context - Amgen's decision reflects a broader trend among pharmaceutical companies to adapt to political and public pressure regarding high drug prices [1] - The move may influence competitive dynamics within the cholesterol medication market, as other companies may need to respond similarly to maintain market share [1]